Cancer that becomes resistant to Tagrisso may still have tumor cells that harbor EGFR mutations, an AstraZeneca spokesperson explained in offering the company’s rationale for adding Tagrisso to ...

WILMINGTON, DE — AstraZeneca presented new data on TAGRISSO® (osimertinib) at the European Lung Cancer Congress (ELCC) 2025, reinforcing its role as a backbone therapy across treatment stages ...

Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace AstraZeneca’s Tagrisso as the new standard of care in first-line EGFR ...

AstraZeneca's EGFR inhibitor Tagrisso has become the go-to therapy for EGFR-mutated non-small cell lung cancer (NSCLC), but now has competition from Johnson & Johnson's Rybrevant and Lazcluze ...

New study results presented at the European Lung Cancer Congress 2025, March 26 to 29, demonstrate the role of AstraZeneca’s (AZN) TAGRISSO, as monotherapy and as the backbone for novel ...

Amid an 18 percent increase in cancer drug sales, J&J executives shared hopes that recent overall survival data for the drug combo will be practice changing.

New study results presented at the European Lung Cancer Congress, ELCC, 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s (AZN) Tagrisso, as monotherapy and as the backbone for novel ...

AstraZeneca saw 18% revenue growth in 2024, boosted by key drugs and global innovation. See here to know why we recommend a ...

J&J opened Q1 2025 pharma earnings Tuesday, reporting sales of $21.9 billion and diluted earnings per share of $4.54. The medicines unit provided $13.9 billion while the medtech unit generated the ...

LAURA Phase III trial of TAGRISSO in unresectable, Stage III EGFRm NSCLC after chemoradiotherapy (CRT) (LBA4). SAVANNAH Phase II trial of TAGRISSO plus savolitinib in advanced EGFRm NSCLC with ...